Special Issue "Challenges to SARS-CoV-2 Vaccines: Infection, Variants, Reinfection"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 17083
Interests: vaccine research and development; coronavirus pathogenesis; coronavirus immunology; SARS-CoV-2 host interaction; SARS-CoV-2 evolution; synthetic virology; reverse genetics
COVID-19 continues to evade our efforts to develop an effective and long-lasting vaccine. Emerging variants have evolved to become more transmissible and to evade host immune responses. Re-infection threatens convalescent and vaccinated patients, with continued risk of illness and transmission to susceptible populations. Despite these challenges, revolutions in vaccine development and regulatory review have resulted in the wide distribution of effective vaccines in record time. SARS-CoV-2, the etiologic agent of COVID-19, continues to be subjected to intense research as the pandemic continues. This Special Issue aims to highlight recent innovations and basic research into how SARS-CoV-2 variants affect pathogenesis, transmission, and re-infection.
To further our understanding of the effects of SARS-CoV-2 evolution on pathogenesis and vaccine efficacy, we are soliciting contributions of original research papers to this Special Issue of MDPI Vaccines. Authors are encouraged to submit work on novel vaccine platforms and designs that have the potential combat SARS-CoV-2 infection variants, pathology, and transmission. Insights into the molecular mechanisms of SARS-CoV-2 immune evasion are also welcome.
Dr. Charles Brandon Stauft
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- variants of concern